OpRegen-Plus

N/A

Report date: 2025/01/26 17:25:17

Base Information

Drug NameOpRegen-Plus
Drug Alias NameHuman embryonic stem cell-derived retinal pigmented epithelial cells (Cell Cure/Hadasit/Hadassah)hESC-derived RPEs (Cell Cure/Hadasit/Hadassah)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Retinal stem cell therapyCell and gene therapy > Cell therapy > Stem cell therapy > Embryonic stem cells therapy
Mechanisms of ActionStem cells modulators
TargetsUpdating
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCellcure Neurosciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCellcure Neurosciences LtdHadasit Bio-Holdings LtdHadassah University Hospital
Inactive CompaniesN/A
Active IndicationsMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A